DNLI Reports Upbeat Longer-Term Data From Hunter Syndrome Study

Denali Therapeutics (DNLI) reported primary analysis data from an early to mid-stage study of its pipeline candidate, tividenofusp alfa (DNL310), in 47 patients with Hunter syndrome (MPS II) over a 24-week treatment period, along with additional long-term follow-up data. DNLI’s wholly-owned program, tividenofusp alfa, is an Enzyme Transport Vehicle-enabled iduronate-2-sulfatase replacement therapy in development for MPS II.Per the additional long-term data readout from the phase I/II study, treatment with t ...